Ruxolitinib-Associated Phaeohyphomycosis: A Case Report

We present the findings of a rare fungal infection phaeohyphomycosis caused by Pleurostoma richardsiae (P. richardsiae) in an immunocompromised 82-year-old male with myelodysplastic syndrome on treatment with the Janus kinase inhibitor ruxolitinib. Hematologists, infectious disease physicians, and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Marples, Rory, Micallef, Milton, Whyte, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575341/
https://www.ncbi.nlm.nih.gov/pubmed/34765385
http://dx.doi.org/10.7759/cureus.19335
_version_ 1784595660669976576
author Marples, Rory
Micallef, Milton
Whyte, Claudia
author_facet Marples, Rory
Micallef, Milton
Whyte, Claudia
author_sort Marples, Rory
collection PubMed
description We present the findings of a rare fungal infection phaeohyphomycosis caused by Pleurostoma richardsiae (P. richardsiae) in an immunocompromised 82-year-old male with myelodysplastic syndrome on treatment with the Janus kinase inhibitor ruxolitinib. Hematologists, infectious disease physicians, and surgeons should consider a fungal etiology in cases of cellulitis refractory to standard treatments in those patients with underlying immune dysfunction and/or in those receiving therapy with ruxolitinib or similar agents.
format Online
Article
Text
id pubmed-8575341
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85753412021-11-10 Ruxolitinib-Associated Phaeohyphomycosis: A Case Report Marples, Rory Micallef, Milton Whyte, Claudia Cureus General Surgery We present the findings of a rare fungal infection phaeohyphomycosis caused by Pleurostoma richardsiae (P. richardsiae) in an immunocompromised 82-year-old male with myelodysplastic syndrome on treatment with the Janus kinase inhibitor ruxolitinib. Hematologists, infectious disease physicians, and surgeons should consider a fungal etiology in cases of cellulitis refractory to standard treatments in those patients with underlying immune dysfunction and/or in those receiving therapy with ruxolitinib or similar agents. Cureus 2021-11-07 /pmc/articles/PMC8575341/ /pubmed/34765385 http://dx.doi.org/10.7759/cureus.19335 Text en Copyright © 2021, Marples et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle General Surgery
Marples, Rory
Micallef, Milton
Whyte, Claudia
Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title_full Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title_fullStr Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title_full_unstemmed Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title_short Ruxolitinib-Associated Phaeohyphomycosis: A Case Report
title_sort ruxolitinib-associated phaeohyphomycosis: a case report
topic General Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575341/
https://www.ncbi.nlm.nih.gov/pubmed/34765385
http://dx.doi.org/10.7759/cureus.19335
work_keys_str_mv AT marplesrory ruxolitinibassociatedphaeohyphomycosisacasereport
AT micallefmilton ruxolitinibassociatedphaeohyphomycosisacasereport
AT whyteclaudia ruxolitinibassociatedphaeohyphomycosisacasereport

Ejemplares similares